A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

NCT06003465 · Completed

Last updated 2026-05-28

This study is testing whether different versions of the investigational drug LY3437943, delivered via different injection devices, produce similar levels in the bloodstream of healthy participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 57 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2023-08 · est. completion 2024-02

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT06003465 ↗

Description as written by the study sponsor.

The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.

Treatments tested

LY3437943 Drug

Administered SC
Test Device

Used to administer LY3437943 SC
Reference Device

Used to administer LY3437943 SC

Main thing measured	Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06003465 ↗